Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.
Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.
复制标题
DOI:
10.1111/eci.12058
复制
发表时间:
2013-04
影响因子:
5.5
通讯作者:
Wang DQ
中科院分区:
文献类型:
--
作者:
Wang HH;Portincasa P;de Bari O;Liu KJ;Garruti G;Neuschwander-Tetri BA;Wang DQ
Cholesterol cholelithiasis is a multifactorial disease influenced by a complex interaction of genetic and environmental factors, and represents a failure of biliary cholesterol homeostasis in which the physical-chemical balance of cholesterol solubility in bile is disturbed. The primary pathophysiologic event is persistent hepatic hypersecretion of biliary cholesterol, which has both hepatic and small intestinal components. The majority of the environmental factors are probably related to Western-type dietary habits, including excess cholesterol consumption. Laparoscopic cholecystectomy, one of the most commonly performed surgical procedures in the US, is nowadays a major treatment for gallstones. However, it is invasive and can cause surgical complications, and not all patients with symptomatic gallstones are candidates for surgery. The hydrophilic bile acid, ursodeoxycholic acid (UDCA) has been employed as first-line pharmacological therapy in a subgroup of symptomatic patients with small, radiolucent cholesterol gallstones. Long-term administration of UDCA can promote the dissolution of cholesterol gallstones. However, the optimal use of UDCA is not always achieved in clinical practice because of failure to titrate the dose adequately. Therefore, the development of novel, effective, and noninvasive therapies is crucial for reducing the costs of health care associated with gallstones. In this review, we summarize recent progress in investigating the inhibitory effects of ezetimibe and statins on intestinal absorption and hepatic biosynthesis of cholesterol, respectively, for the treatment of gallstones, as well as in elucidating their molecular mechanisms by which combination therapy could prevent this very common liver disease worldwide.
登录
查看更多内容
影响因子:
2.9
作者:
Davis, KG;Wertin, TM;Schriver, JP
通讯作者:
Schriver, JP
影响因子:
13.5
作者:
DUANE, WC;HUNNINGHAKE, DB;GEBHARD, RL
通讯作者:
GEBHARD, RL
DOI:
10.1007/bf02020929
发表时间:
1971-01-01
期刊:
ZEITSCHRIFT FUR ERNAHRUNGSWISSENSCHAFT
影响因子:
--
作者:
DAM, H;PRANGE, I;FENGER, HJ
通讯作者:
FENGER, HJ
DOI:
10.1016/0005-2760(94)90096-5
发表时间:
1994-11-17
期刊:
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM
影响因子:
--
作者:
BRAVO, E;BOTHAM, KM;CANTAFORA, A
通讯作者:
CANTAFORA, A
影响因子:
37.8
作者:
Ballantyne, CM;Houri, J;Veltri, EP
通讯作者:
Veltri, EP